Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Cochlear ( (AU:COH) ) just unveiled an update.
Cochlear Limited has disclosed a change in director Karen Lee Collett Penrose’s indirect shareholding in the company following an on-market trade. Penrose, whose interest is held via GKP Acquisitions Pty Ltd as trustee for the Karen Lee Superannuation Fund, acquired 100 fully paid ordinary shares at A$201.22 each on 18 February 2026.
The transaction increases Penrose’s indirect holding from 1,420 to 1,520 Cochlear shares, signalling a modest uplift in her financial exposure to the company. The company confirmed that the trade did not occur during a closed period requiring prior written clearance, indicating routine personal investment activity rather than a flagged governance or compliance event.
The most recent analyst rating on (AU:COH) stock is a Buy with a A$295.00 price target. To see the full list of analyst forecasts on Cochlear stock, see the AU:COH Stock Forecast page.
More about Cochlear
Cochlear Limited is a medical device company specialising in implantable hearing solutions, including cochlear implants and related technologies. The company targets patients with moderate to profound hearing loss and operates globally, serving healthcare providers, audiology professionals and recipients seeking advanced hearing restoration solutions.
Average Trading Volume: 130,625
Technical Sentiment Signal: Sell
Current Market Cap: A$13.07B
For an in-depth examination of COH stock, go to TipRanks’ Overview page.